Abstract:
The invention relates to measuring the decrease in phosphorylation of the fatty acid binding protein found in the milk fat globule membrane of bovine or human milk to detect growth hormone treatment in animals. MFGM of cows treated with bST displays weaker FABP autophosphorylation activity than non treated cows. MFGM isolated from cows treated with bST have significantly reduced levels of phosphorylated FABP. The bST test of the present invention can be used not only to determine whether the animal producing the milk has been treated with bST, it can also be used to determine the efficacy of bST on milk production. Dairy managers could thus base their decision on whether to continue bST treatment on such a test.
Abstract:
The present invention relates to a method of imparting pathogen resistance to plants. This involves applying a hypersensitive response elicitor polypeptide or protein in a non-infectious form to a plant under conditions where the polypeptide or protein contacts cells of the plant. The present invention is also directed to a pathogen resistant plant and a composition for imparting pathogen resistance to plants.
Abstract:
A recombinant adenovirus comprising a chimeric fiber protein and a therapeutic gene, a method of gene therapy involving the use of such an adenovirus, and an adenoviral transfer vector for the generation of such a recombinant adenovirus are provided.
Abstract:
The invention concerns genes encoding recombinases that can be used to promote homologous recombination in eukaryotic cells. The application teaches methods by which a recombinase of one species can be used to isolate a homologous recombinase of a different species and methods to identify the isolated homologs. Recombinases from Ustilago maydis and Saccharomyces cerevisiae are specifically included in the invention. The invention encompasses the method of producing an isolated recombinase protein in a prokaryotic cell and recovering the product in an active form. The invention also encompasses a genetically engineered gene which encodes a non-naturally occurring recombinase that causes a greater rate of recombination than does the naturally occurring recombinase. The invention further encompasses the use of recombinase proteins and of recombinase genes to promote homologous recombination, including recombination between a host cell genome and a chimeric oligonucleotide, i.e., an oligonucleotide having both RNA and DNA bases.
Abstract:
The present invention is directed to a vector for transferring heterologous DNA into a plant cell. The vector is based on the bacterial artificial chromosome (BAC) vector designed for the construction of genomic libraries with large DNA inserts, and the binary (BIN) vector designed for Agrobacterium-mediated plant transformation. The BIBAC vector according to the subject invention allows the construction of plant genomic libraries with large DNA inserts that can be directly introduced into plants by transformation mediated by Agrobacterium.
Abstract:
A process for preparing hyperbranched polymers from AB monomers using a self-constructing approach is disclosed. Hyperbranched polymers of a living-like character produced by such process are also disclosed.
Abstract:
Novel sequences in the genome of a wild type isolate of chicken infectious anemia virus are described. The amino acid sequence of a polypeptide, VP1, encoded by a novel sequence is also disclosed. Additionally, disclosed are the unexpected properties of the isolate which are related to novel amino acids positioned in the amino acid sequence of this isolate's VP1, as compared to the sequence of VP1 found in cell culture-adapted strains; and use of the novel sequences and their respective polypeptides in strategies to control chicken infectious anemia such as by vaccination.
Abstract:
The present inention relates to a process for ex vivo expansion of hematopoietic progenitor cells. This process is particularly useful in conjunction with a process for conducting autologous hematopoietic progenitor cell transplantation. In this process, hematopoietic progenitor cells are obtained from a patient prior to cytoreductive therapy. The hematopoietic progenitor cells are then expanded ex vivo with bone marrow endothelial cells or with one or more cytokines therefrom to produce a cellular preparation with an increased number of hematopoietic progenitor cells. The cellular preparation is then administered to the patient in conjunction with or after cytoreductive therapy.
Abstract:
The present invention relates to bone marrow endothelial cells characterized by their ability to support adhesion of megakaryocytes and bone marrow mononuclear cells as well as by their being a source for one or more cytokines supporting either progenitor cell proliferation, differentiation of pluripotent progenitor cells to megakaryocytes, or platelet formation by megakaryocytes. The bone marrow endothelial cells of the present invention are isolated by recovering bone marrow spicules from bone marrow, digesting the bone marrow spicules with one or more proteolytic enzymes, recovering microvessel fragments from the digested bone marrow spicules, and growing the microvessel fragments to form bone marrow endothelial cells.
Abstract:
The invention relates to a gene isolated from Thermomonospora fusca, wherein the gene encodes a thermostable cellulase. Disclosed is the nucleotide sequence of the T. fusca gene; and nucleic acid molecules comprising the gene, or a fragment of the gene, that can be used to recombinantly express the cellulase or a catalytically active polypeptide thereof, respectively. The isolated and purified recombinant cellulase or catalytically active polypeptide may be used to hydrolyze substrate either by itself; or in combination with other cellulases, with the resultant combination having unexpected hydrolytic activity.